November 1st 2021
Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.
Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.
October 25th 2021
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.
Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.
October 18th 2021
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.
Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.
October 11th 2021
Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.
An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.
September 20th 2021
Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
September 13th 2021
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.
Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.
September 7th 2021
A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.
Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.
August 30th 2021
Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.
A panel of experts discuss treatment options based on efficacy and out-of-pocket cost for patients.
May 26th 2021
Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.
May 18th 2021
Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
February 6th 2021
Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.
March 31st 2020
Mark A. Socinski, MD, discusses his recommendations for conducting molecular testing in lung cancer.